Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Profit After Tax: 2019-2024

Historic Profit After Tax for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$187.4 million.

  • Keros Therapeutics' Profit After Tax rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 135.50%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
  • Keros Therapeutics' Profit After Tax amounted to -$187.4 million in FY2024, which was down 22.46% from -$153.0 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Profit After Tax ranged from a high of -$45.4 million in FY2020 and a low of -$187.4 million during FY2024.
  • Its 3-year average for Profit After Tax is -$148.3 million, with a median of -$153.0 million in 2023.
  • Data for Keros Therapeutics' Profit After Tax shows a maximum YoY crashed of 267.71% (in 2020) over the last 5 years.
  • Keros Therapeutics' Profit After Tax (Yearly) stood at -$45.4 million in 2020, then declined by 29.50% to -$58.7 million in 2021, then tumbled by 78.20% to -$104.7 million in 2022, then plummeted by 46.15% to -$153.0 million in 2023, then declined by 22.46% to -$187.4 million in 2024.